Cart (0 Items)
Your cart is currently empty.
View ProductsTarextumab Biosimilar – Anti-CD52 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Tarextumab Biosimilar - Anti-CD52 mAb - Research Grade |
|---|---|
| Source | CAS 1359940-55-8 |
| Species | Caninized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Tarextumab,OMP-59R5,CD52,anti-CD52 |
| Reference | PX-TA1326 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG2-kappa-lambda |
| Clonality | Monoclonal Antibody |
Description of Tarextumab Biosimilar - Anti-CD52 mAb - Research Grade
General information on Anti-CD52[Homo sapiens] (Tarextumab) Monoclonal Antibody
Tarextumab has beeninvestigated for the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
Related products
Antigen
CD52 Recombinant Protein
PX-P4084 310€
SIL
Stable Isotope Labelled Tarextumab Biosimilar – Anti-CD52 mAb – Research Grade
PX-TA1326-SIL 15000€
ELISA
Reviews
Il n’y a pas encore d’avis.